{"entity":{"id":"nct06323148","kind":"trial","name":"Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022)","aka":[],"tldr":"A phase 3 trial of osimertinib in lung cancer, run by Fudan University, not yet recruiting.","summary":"Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022) is a phase 3, randomised interventional study registered as NCT06323148 by Fudan University, with a registry enrolment figure of 226 participants, started 2024-04-01 and due to reach its primary completion in 2026-03-31. Interventions recorded: Osimertinib; No adjuvant therapy. Conditions listed: Lung Cancer; EGFR Gene Mutation; Minimal Residual Disease. Primary outcome: The 3-year Disease-Free Survival (DFS) rate between the observation group and the osimertinib treatment group.. Lung eligibility wording from the registry: \"Histologically confirmed diagnosis of non-small cell lung cancer\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT06323148","url":"https://clinicaltrials.gov/study/NCT06323148"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["egfr-mutant-nsclc","resectable-nsclc"],"sections":[],"technologies":["kinase-inhibitors","mrd-testing"],"targets":[],"drugs":["osimertinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06323148","phase":"3","setting":"Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA","sponsor":"Fudan University","enrolled":226,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06323148/","neighbours":{"cancer":[{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/"},{"id":"resectable-nsclc","kind":"cancer","name":"Resectable stage I to III non-small-cell lung cancer","route":"/cancers/resectable-nsclc/"}],"technology":[{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}